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A B S T R A C T
Patients with Atopic Dermatitis (AD) suffer from inflamed skin and skin barrier defects. Proper formation of the
outermost part of the skin, the stratum corneum (SC), is crucial for the skin barrier function. In this study we
analyzed the localization and activity of lipid enzymes β-glucocerebrosidase (GBA) and acid sphingomyelinase
(ASM) in the skin of AD patients and controls. Localization of both the expression and activity of GBA and ASM
in the epidermis of AD patients was altered, particularly at lesional skin sites. These changes aligned with the
altered SC lipid composition. More specifically, abnormal localization of GBA and ASM related to an increase in
specific ceramide subclasses [AS] and [NS]. Moreover we related the localization of the enzymes to the amounts
of SC ceramide subclasses and free fatty acids (FFAs).
We report a correlation between altered localization of active GBA and ASM and a disturbed SC lipid com-
position. Localization of antimicrobial peptide beta-defensin-3 (HBD-3) and AD biomarker Thymus and
Activation Regulated Chemokine (TARC) also appeared to be diverging in AD skin compared to control. This
research highlights the relation between correct localization of expressed and active lipid enzymes and a normal
SC lipid composition for a proper skin barrier.
1. Introduction
Atopic Dermatitis (AD) is a multifactorial disease in which both
immunological aspects and skin barrier defects contribute to clinical
manifestations as erythema, xerosis and pruritis. The interplay between
inflammation and skin barrier in this disease is complex, and it is hy-
pothesized that a skin barrier dysfunction may facilitate exogenous
compounds (e.g. pathogens, allergens) to penetrate the skin and pro-
voke an immune response [1]. Subsequently, this immune response
may also affect the barrier properties of the skin. This is also known as
the “outside–inside–outside” model of AD pathogenesis [2,3]. None-
theless, AD is known to be a heterogeneous disease that can be driven
by activation of the adaptive immune response, along with being the
initiator that activates key TH1, TH17 and TH22 cytokine pathways [4].
The strongest predisposing factor for developing AD is loss-of-
function mutations in the filaggrin gene (flg) [5,6]. The protein filaggrin
is an essential component for a proper formation of the Stratum Cor-
neum (SC), the outermost skin layer that functions as the primary
physical skin barrier. The SC is the non-vital final keratinocyte differ-
entiation product forming the outermost layer of the skin. It consists of
multiple layers of corneocytes (dead cells) embedded in an extracellular
lipid matrix and plays an eminent role in the barrier function of the
skin. The breakdown products of filaggrin – forming a substantial part
of the natural moisturizing factor (NMF) – are essential for water
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retention in theSC. Additionally, the NMF is important for maintaining
a physiologic acidic environment in the SC, supporting an optimal skin-
pH and water level for proper enzyme activity in the skin [7,8]. Several
of these skin enzymes play a crucial role in generating key barrier
components of the SC, the SC lipids, which form a highly ordered in-
tercellular matrix [9,10]. The composition of the SC lipid matrix is
crucial for a proper skin barrier, and changes in these lipids are related
to several skin barrier diseases [11,12]. The main SC lipids are cer-
amides, free fatty acids (FFAs) and cholesterol. Ceramide synthases are
essential for the formation of ceramides de novo. To store the ceramides
in the viable cells, the ceramides are converted to glucosylceramides
and sphingomyelin by the enzymes glucosylceramide synthase and
sphingomyelin synthase, respectively (as reviewed in [13]). Besides
ceramides also free fatty acids (FFAs) reside in the lipid matrix of the
SC. Proper expression of stearoyl CoA desaturase (SCD) and ELOVL1-7
(elongation of very long chain fatty acids 1–7) have been shown to be
key for a proper FFA and ceramide composition [13]. An impaired skin
barrier is typically monitored by an increased transepidermal water loss
(TEWL. AD patients suffer from an increased TEWL (reduced skin
barrier). This increased TEWL is correlated to changes in the SC lipids,
particularly in two key classes: the ceramides, and their precursors the
FFAs [14]. Whereas FFAs contain a single acyl chain, ceramides contain
two long chains attached to one polar head group. In SC both the head
group and carbon chain length show a wide variation in molecular
architecture [15]. To distinguish all SC ceramides, they are categorized
in subclasses based on their architecture, illustrated in Supplemental
Fig. 1. The SC ceramide composition in AD patients is changed. Com-
pared to control skin, lesional AD skin demonstrates a significant de-
crease in the average carbon chain length of both ceramides and FFAs
[16–18]. In addition, a (relative) increase in [AS] and [NS] ceramides
in lesional skin has been observed [19–21]. The reason why particularly
ceramides [AS] and [NS] are increased in barrier disrupted skin is not
fully understood, but likely originates from changes in the epidermal
biosynthesis of the SC ceramides [12,22].
A pivotal step in this ceramide conversion is the final process in
which ceramide precursors – glucosylceramides and sphingomyelins –
are extruded from the Stratum Granulosum (SG) keratinocytes into the
extracellular environment at the SG/SC interface [14]. During this ex-
trusion process of lipids and their corresponding enzymes, the ceramide
precursors transform into their final barrier constituents. Here, gluco-
sylceramides and sphingomyelins are converted by respectively β-glu-
cocerebrosidase (GBA) and acid sphingomyelinase (ASM) (Fig. 1). Both
GBA and ASM will convert their substrates into ceramides, but con-
version by ASM will lead to only ceramide subclasses [AS] and [NS],
whereas ceramide formation via GBA may lead to ceramides of any
subclass [23,24]. It is known that the expression of these enzymes is
mildly changed in the epidermis of some AD subjects, particular at le-
sional skin sites [25–27]. However, not all reported changes in the SC
ceramides in AD patients could be explained by the expression of GBA
and ASM [28]. Literature suggests that micro-environmental factors
like SC water content and local skin-pH are essential for proper activity
(besides expression) of these enzymes [29,30]. The skin microbiome
and inflammation are changed in AD [31–33] and could therefore
consequently have an effect on the SC lipid composition. This has not
been studied previously, thus we additionally examined the localization
of Human beta defensing (HBD)-3 as a readout for the microbiome, plus
it has been reported to be decreased in AD. Furthermore we included
Thymus and Activation Regulated Chemokine (TARC), which is in-
volved in Th2 cell migration and has been confirmed as a biomarker for
AD severity [32,33]. This also provides the opportunity to research
whether the localization of these AD markers change concordantly with
GBA and ASM localization.
We visualized in situ enzyme expression and activity of GBA and
ASM in human skin tissue of AD subjects and controls and analyzed the
SC ceramides and FFas by LC/MS. In addition, we examined several AD
markers (both locally and systemically) to study the relationship be-
tween the SC lipids and the inflammatory aspects, as it is known that
cytokines may induce lipid abnormalities in atopic skin [34,35]. Our
findings elucidate the relation between localization of – particularly
active – GBA and ASM, versus the SC lipid composition. In addition, this
study elaborates on the clinical relevance by relating these enzymes and
SC lipid composition to biologically/clinically important parameters
like TEWL and disease severity scores [36].
2. Materials and methods
2.1. Subject inclusion and skin sample processing
The study was conducted according to the Declaration of Helsinki
principles. Caucasian AD patients and control volunteers of age 18–40
were included in the study and assessed using SCORAD (SCORing
Atopic Dermatitis) [37] and EASI (Eczema Area and Severity Index)
[38]. A full overview of all exclusion criteria is provided in supple-
mental materials and methods. Individuals had a 4-week washout
period during which it was not allowed to use soaps or cosmetics on the
ventral forearms. Subjects with lesional AD skin were put on standard
medication that did not contain any interfering lipids (see ‘Use of
standardized formulations’ in the supplement). After 4 weeks the par-
ticipants were scored again for SCORAD and EASI. This was followed by
monitoring skin-pH and TEWL in depth after SC removal by tape
Fig. 1. Schematic overview of formation SC lipid layers at the SG/SC-interface. 1. Lamellar Bodies (LBs) in the keratinocytes are filled with ceramide precursors
glucosylceramides and sphingomyelins together with the enzymes GBA and ASM. 2. Extrusion process of the lipids and lipid enzymes. 3. Conversion of gluco-
sylceramides and sphingomyelins by respectively GBA and ASM to ceramides. 4. Formation of the extracellular stacked lipid layers: the lipid barrier in the SC.
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stripping from a marked area on their ventral forearm. TEWL was
measured with a closed chamber evaporimeter (Aqua Flux AF200: Biox
Systems Ltd., London, UK) and skin-pH was measured with a skin-pH
Portable Meter - HI99181 – (Hanna Instruments, Nieuwegein, NL).
Subsequently two 4mm punch biopsies were collected from the non-
lesional AD skin and skin from controls, adjacent to the tape stripped
sites. Two additional biopsies were obtained from three AD patients
that had lesional skin sites on their ventral forearms. Biopsies were used
either for SC lipid analysis or were snap frozen with matrix specimen
Tissue-Tek (Sakura Finetek, Alphen a/d Rijn, Netherlands) in liquid
nitrogen. Frozen samples were cut to 5 μm thick sections (Leica
CM3050s, Leica Microsystems, Germany), placed on SuperFrost plus
microscope slides (VWR International, Netherlands) and stored at
−80 °C prior to being used for enzyme studies.
2.2. SC lipid isolation and analysis
The SC of one of the biopsies was isolated by a common trypsin
digestion procedure [39], followed by SC lipid isolation with use of an
extended Bligh and Dyer extraction [40,41]. The SC lipids were re-
constituted in heptane:chloroform:methanol (95:2.5:2.5) and the exact
ceramide and FFA composition was finally determined by liquid chro-
matography/mass spectrometry (LC/MS), as previously reported [41].
Briefly, a normal phase pva-column (100×2.1mm i.d., 5 μm particle
size; YMC Kyota, Japan) attached to and Acquity UPLC H-class device
(Waters, Milford, MA, USA), programmed with an elution gradient of
heptane towards heptane:isopropanol:ethanol (50:25:25), was used to
separate the ceramides subclasses by chromatography. A Waters Xevo
TQ-S MS, equipped with an atmospheric pressure chemical ionization
(APCI) source was used for all mass analysis in positive ion full scan
mode of the lipids. Data presented in absolute amounts (nmol/μg SC)
was obtained by applying our reported quantitative model by using
deuterated internal standards (Ceramides EOS and NS).
For FFA analysis, a new method was developed based on our pre-
viously reported analysis [42]. A Purospher Star LiChroCART column
(55× 2 mm i.d., 3 μm particle size; Merck, Darmstadt, Germany) was
used to separate FFAs while a solvent gradient of acetonitrile:H2O
(90:10) to methanol:heptane (90:10) was maintained at 0.5 mL/min.
For ionization optimization, addition of 2% chloroform and 0.005%
acetic acid led to stable [M+Cl]− and [M-H]− traces, both analyzed in
SIR negative ion mode using a Waters XEVO TQ-S MS with an IonSabre
APCI MkII probe. Details of this method are provided in the supple-
ment.
2.3. Statistics
Statistical tests were performed using Graphpad Prism v6
(GraphPad Software, La Jolla California USA) and IBM SPSS Statistics
v24 (IBM, New York, NY). Most data appeared non-normally dis-
tributed, hence we used non-parametric statistics: significant ordinal
trends in the SC lipid quantities (ceramides and FFAs) were determined
using the Jonckheere-Terpstra trend tests. Spearman's ρ were calculated
to indicate correlation coefficients. Significance was set at the p < 0.05
level.
2.4. Immunohistochemical staining of ASM, GBA, HBD-3 and TARC
Skin cryosections were washed three times with PBS and blocked in
PBS containing 1% (v/v) BSA and 2.5% (v/v) horse serum. Next, sec-
tions were incubated overnight at 4 °C with any of the primary anti-
bodies diluted in 1% BSA in PBS. Thereafter, sections were washed with
PBS and labeled for 1 h at room temperature with secondary antibody
diluted in 1% BSA in PBS. Then sections were washed twice in PBS,
once in demi-H2O and finally mounted with Vectashield with diami-
dino-phenylindole solution (DAPI, Vector Laboratories, Burlingame,
CA). Antibody details and dilution factors are depicted in Table 1.
2.5. In-situ ABP labeling GBA
Active GBA was visualized by labeling with the ABP MDW941 as we
reported previously [43]. Briefly, skin cryosections were washed in
MilliQ with 1% (v/v) Tween-20 (Bio-Rad Laboratories), followed by
incubation with 100 nM of MDW941 in McIlvain buffer (150mM citric
acid-Na2HPO4 (pH 5.2)) with 0.2% (w/v) sodium taurocholate and
0.1% (v/v) Triton X-100 for 1 h at 37 °C. Then samples were washed
once with MilliQ with 1% (v/v) Tween-20 and afterwards three times
with MilliQ water. Mounting was performed using Vectashield with
DAPI solution.
2.6. In-situ zymography ASM
Active ASM was visualized by our recently developed in situ zy-
mography method using 6-HMU-PC (Moscerdam, Oegstgeest, the
Netherlands) as ASM specific substrate [44]. Skin samples were washed
in MilliQ with 1% (v/v) Tween-20. The sections were incubated in
0.1M sodium acetate buffer pH 5.2 containing 0.5mM 6-HMU-PC in,
0.02% (w/v) sodium azide and 0.2% (w/v) sodium tauricholate at 37 °C
for 1 h. Subsequently, samples were dip-washed twice with MilliQ with
1% (v/v) Tween-20. Mounting was performed using Vectashield with
Propidium iodide (PI, Vector Laboratories, Burlingame, CA).
2.7. Fluorescence microscopy
Microscopy images were taken with a Zeiss Imager.D2 microscope
connected to a ZeissCam MRm camera (Zeiss, Göttingen, Germany)
with objective magnification 10× and lens magnification between 10-
63× (with immersion oil). Zen 22,012, blue edition (Zeiss) was used for
image processing. Exposure times were kept constant for each in-
dividual experiment. Gamma was set to 1.0 for all measurements.
Enzyme activity was determined at its optimal magnification 63×.
Activity of ASM was visualized by 6-HMU at λex= 380 nm and
λem=460 nm, whereas active GBA was visualized with ABP MDW941
at λex= 549 nm, λem=610 nm. Microscopy images were in-
dependently scored by two researchers on the location of GBA, ASM,
HBD-3 and TARC.
3. Results
This study cohort consisted of ten patients diagnosed with AD and
five controls. Three AD patients had lesional regions on their arms
during the study period. A summary of the results with respect to (local)
SCORAD, EASI, TEWL and skin-pH per time point is provided in Fig. 2.
In agreement with previous studies, our AD cohort demonstrated an
elevated baseline TEWL for non-lesional as well as lesional skin regions
in comparison to control skin [45]. In addition, skin-pH values were in
similar ranges as reviewed elsewhere [46]. These general parameters
support the representativeness of this AD cohort in relation to estab-
lished literature [37,38,45,46].
3.1. Location of expressed enzyme does not predict the location of active
enzyme
We first studied the localization of GBA expression in the skin
cryosections of the control subjects. The top panel in Fig. 3 shows the
expression of GBA mainly concentrated at the interface between the
viable epidermis and SC (SG/SC-interface). Active GBA was visualized
using the activity based probe MDW941. Concerning the intensity of
the signal, a substantial intra- and inter-individual variation was ob-
served. Therefore, we focused on the location of the activity in this
study (Supplemental Fig. S2). In all controls, the active enzyme was
primarily observed in the SC, no active GBA was observed in the viable
epidermis. Active GBA was present in the SC lipid matrix surrounding
the corneocytes: either throughout all SC layers, or in the lower regions
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of the SC. Note that the signal intensity is very heterogeneous between
subjects and even within a single skin section, but localization remains
in the SC lipid matrix for all controls.
When focusing on ASM expression in the control skin sections, the
expression was present throughout the viable epidermis. The activity of
ASM was determined by zymography. The intensity of this signal was
also very heterogeneous, even within a single skin cryosection of a
subject. In one subject (nr. 5) no ASM activity was detected. The lo-
cation of ASM activity was detected mainly in the lower layers of the SC
near the SG/SC-interface or scattered throughout the whole SC, but no
activity signal was encountered in the viable epidermis.
3.2. Lesional AD skin shows less localized active GBA and ASM compared
to control skin
Lesional skin sections from three subjects were available for ana-
lysis. We first noted more keratinocyte layers in the viable epidermis
compared to the control skin sections (Supplemental Fig. S2).
Moreover, in the lesional skin of patient #15 the SC appeared thicker
and at some sections, corneocytes appeared swollen (Supplemental Fig.
S2). The expression of GBA at lesional skin sites was examined (Fig. 3,
bottom panel). In patient #15 the expression of GBA was very similar to
that in the control skin. In patient #13, GBA expression was sometimes
observed at the SG/SC-interface, but mostly in the outermost kerati-
nocyte layer in the viable epidermis close to the SG/SC-interface.
Concerning patient #14, no GBA expression was detected at the lesional
site, instead a diffuse signal was present in the whole viable epidermis.
Additionally, in this patient nuclear expression was observed. When
focusing on active GBA, in general this was localized in the SC matrix.
In some parts of the sections of subject #13, no active GBA could be
detected. However, in the majority of the cases of areas where activity
was observed, a distribution throughout all the SC layers was observed.
In skin sections of the other two patients active GBA was observed in
the SC matrix, but mainly in the middle and outer layers of the SC and
not in the lower layers of the SC.
ASM expression was not detected in patient #15, whereas the le-
sional sites of the other two subjects demonstrated expression at loca-
tions similar to that observed in the control skin sections. As far as
active ASM is concerned, all lesional sections throughout all the SC lipid
layers demonstrated activity. In the case of patient #14 the distribution
throughout the SC was more scattered compared to the more evenly
spread localization observed in the other two AD patients. Because the
signal of ASM activity was throughout the whole SC of subject #15, the
swollen corneoctes at the lesional sites of the SC were even more ap-
parent.
Table 1
Overview primary and secondary antibodies.
Antibody Dilution ratio Binding Antibody brand
1st Anti-GBA 1:150 Human anti rabbit Abcam (ab125065)
Anti-ASM 1:150 Human anti mouse Novus (NBP2-45889)
Anti-HBD-3 1:1500 Human anti rabbit Abcam (ab19270)
Anti-TARC 1:100 Human/rat/mouse anti rabbit Abcam (ab182793)
2nd Rhodamine red 1:300 Goat anti rabbit Jackson ImmunoResearch (711-295-152)
Cy3 1:1000 Goat anti mouse Abcam (ab97035)
Fig. 2. Schematic overview experimental set up and scoring of the cohort. T0: SCORAD and EASI parameters of volunteers and AD patients. T4 weeks: SCORAD, EASI,
TEWL and pH parameters of controls and AD patients. Skin samples from arm regions and two biopsies were taken from all subjects. From 3 AD patients non-lesional
and lesional skin samples were taken. Furthermore venipuncture and tape stripping was performed.
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Fig. 3. In situ expression and activity localization of GBA and ASM within skin sections of control, non-lesional AD and lesional AD skin. Microscopy images showing
in which skin layers expressed and active enzymes are localized. Depicted are which localization patterns can be found in each subject. Bold numbers show its main
occurrence per subject. Italic numbers demonstrate the less abundant patterns.
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3.3. Non-lesional AD skin demonstrates a high variety in localization of
active enzymes
A large variation was observed between the different subjects for
GBA and ASM of non-lesional AD skin: localization patterns of active
GBA and ASM varied between very comparable to control skin and si-
milar to a lesional appearance. All the sections showed a GBA and ASM
expression pattern similar to the control subjects, with two exceptions:
i) Patient #9 showed additionally intra nuclear GBA expression; ii) non-
lesional skin sections of patient #15 showed no ASM expression signal.
The localization of active GBA was observed throughout the whole SC
or in the lower layers of the SC, as described above for the control
subjects. However, the localization in patient #7 was sometimes absent
in the lower layers of the SC, corresponding with a more lesional dis-
tribution pattern. Active ASM localization was confined throughout the
whole SC, either in a smooth or in a scattered pattern. Only patient #14
demonstrated no active ASM signal.
When combining all these findings we observe that the localization
of active enzyme appeared more variable than the location of expressed
enzyme. In general, active GBA and ASM are less localized near the SG/
SC-interface in lesional and some non-lesional AD skin regions. As these
changes in localization of enzyme activity may affect the SC ceramide
composition, we thoroughly analyzed the SC lipids for each subject.
3.4. Increase in [AS] and [NS] ceramides relate with enzyme phenotype
and disease severity
We quantified the SC ceramides for each specific subclass and chain
length Additional data on specific ceramides or glucosylceramides is
listed in Supplemental Fig. S3 and Supplemental Tables 2 and 3. Fig. 4A
demonstrates that AD patients have less absolute amount of total cer-
amides, particularly at lesional skin sites. Ceramide [NP] and [NH]
were mostly reduced, as well as the EO ceramides. In contrast, cer-
amides [NS] and [AS] increased in absolute (and relative) amount in
AD. Close examination revealed that the increase in these subclasses
was dominated by ceramides with a very short chain length being 34
carbon atoms in total chain length, the so called C34 ceramides (Fig. 4B
and Supplemental Fig. S4). We then related the amount of ceramides
[AS]+ [NS] to the different categories of activity patterns observed for
ASM as described above (Fig. 4C). The absence of clear ASM activity or
clear localization near the viable epidermis and SG/SC-interface coin-
cided with a relatively low [AS] and [NS] amount. In addition, subjects
that had a more dispersed ASM activity localization compared to con-
trol subjects, demonstrated the most deviating amount of ceramides
[AS] and [NS]. Thus, less localized active ASM around the SG/SC-in-
terface correlates with an increased (and more varying) amount of [AS]
and [NS]. We also observed the amount of ceramides [AS] and [NS]
coinciding with an increase in local disease severity (Fig. 4D). Fur-
thermore, a correlation was observed for active GBA and the ceramides
that are synthesized by this enzyme only (all ceramides minus [AS] and
[NS]), as is depicted in Fig. 4E. Absence of GBA activity near the SG/SC-
interface results in a reduced amount of ceramides synthesized by GBA.
Therefore, active GBA near the SG/SC-interface is crucial for a normal
amount of ceramides synthesized by that enzyme.
The increase in short chain length ceramides and decrease in very
long EO ceramides reduces the mean ceramide chain length in patients
Fig. 4. SC lipid data in control, non-lesional and lesional AD skin A. Bar plots of average amount of ceramide subclasses in the SC. B. Dot plot amount of C34
ceramides plotted versus the total amount of [AS]+ [NS] ceramides. C. Dot plot total amount of [AS]+ [NS] ceramides plotted against the location of active ASM in
the skin. D. Dot plot LocalSCORAD plotted against the total amount of [AS]&[NS] ceramides, E. Dot plot total amount of SC ceramides without [AS]+ [NS]
compared to the location of active GBA location in the skin. F. Bar plots of average amount of SC FFAs categorized by length and degree of unsaturation. Significant
ordinal trends (Jonckheere-Terpstra tests) for the ceramide and FFA quantities in A and F, respectively are shown for each lipid with a * (p < 0.05). Horizontal lines
in C and E represent means, and ρ-values in B and D depict Spearman correlations.
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with AD, especially in lesional skin [18]. As the changes in ceramide
chain length may be related to an impaired fatty acid elongation pro-
cess [47], we quantified the FFA composition as well (Fig. 4F). The
calculated molar ratio ceramides: FFAs was 0.61 ± 0.18 in the control
group, 0.59 ± 0.13 in non-lesional AD and 1.06 ± 0.66 in lesional AD
skin. Note that we excluded the short chain FFAs due to notorious
contamination of C16:0 and C18:0, even nowadays in ultra-pure or-
ganic solvents. This explains the difference in ratio-outcomes when
comparing them to literature values [48,49]. We observed also a de-
crease in absolute amount of FFAs in AD skin, particularly for ceramides
with chain length of 23 carbon atoms or higher. This could be an in-
dication for a relation between the decrease in FFA chain length to the
increase in short chain ceramides belonging to the [AS] and [NS]
subclass.
3.5. TARC and HBD-3 are less localized around the SG/SC-interface in
lesional AD skin sections
Besides the lipid enzymes, we also studied whether key inflamma-
tion markers (for AD) were changed systemically and locally.
Systemically, we studied levels of TARC, Interleukin-22 and soluble IL-2
receptorin plasma, but no difference in these parameters between
control and AD subjects was observed in this study cohort (data not
shown).
In the skin the localization of TARC and HBD-3 were studied as a
readout for inflammation and skin microbiome respectively. This is
shown in Fig. 5, for the control subjects and AD patients #13, #14 and
#15 non-lesional and lesioanl regions. HBD-3 is mainly localized in the
viable epidermis and occasionally slightly more confined around the
SG/SC-interface in most control and non-lesional skin sections. There
are non-lesional and lesional skin sections where HBD-3 is also present
in the SC (non-lesional of subjects #14 and #15, lesional skin of subject
#13). And in one patient, at the lesional site HBD-3 was more profound
in the SC layers (#15).
Concerning the localization of AD marker TARC, its presence was
generally in the viable epidermis and localized around the SG/SC-in-
terface in control and non-lesional skin sections. In the lesional and
some non-lesional skin sites, the expression of TARC was more abun-
dant in the SC, either mainly in the bottom layers (non lesional section
of #15 and lesional sites of #11 and #12) or throughout the whole SC
(lesional skin section #15). Thus, delocalization of TARC was mainly
detected in (inflamed) lesional AD skin as was observed with the active
enzymes GBA and ASM.
4. Discussion
This study is the first that determines in one cohort of AD patients
altogether the location of expressed and active SC lipid enzymes, and
additionally relates this to a fully quantified SC ceramide and FFA
composition. Here we demonstrate AD patients have an altered locali-
zation of GBA and ASM, particularly at lesional skin sites. The changes
observed in (active) enzyme localization relate to altered ceramide le-
vels and the ceramide subclass profile. These changes in SC lipids
correlated with a disturbed skin barrier and increased local disease
severity.
Although our study cohort is small, it has identical clinical char-
acteristics as comparable studies reported previously (i.e. TEWL,
SCORAD, SC, skin barrier lipid properties) [17–19,28,50,51]: i) On a
general level, AD patients demonstrate a decrease in amount of SC li-
pids (both ceramides and FFAs), which is more substantial at lesional
skin sites. ii) When observing the SC lipids in more detail, a shift to-
wards shorter ceramides and FFAs is seen in AD patients. iii) An in-
crease in subclasses that are particularly related to ASM ([AS] and
[NS]) was observed at the expense of ceramide [NP] and [NH], a fea-
ture of AD that is observed in almost every AD cohort.
When correlating the SC lipid composition to the enzyme
expression/activity, one should realize that there is a time-aspect dif-
ference between both parameters: The ceramide composition is the
result of an accumulation of the lipid synthesis products for at least
20 days prior to the study day, whereas the biopsies and in-situ ex-
pression/activity images are visualizations at a specific time point – the
study day itself. Nevertheless, despite this time-issue and the small
sample-size of our cohort, we were able to establish clear changes in the
lipid enzymes and correlate these to the SC ceramide phenotype.
Fig. 5. In situ localization of HBD-3 and TARC within skin sections of control,
non-lesional AD and lesional AD skin. Microscopy images of skin sections
showing in which skin layers HBD-3 and TARC are localized. Depicted are
which localization patterns can be found in each subject. Bold numbers show its
main occurrence per subject. Italic numbers demonstrate which patterns also
appear in subjects, but are not the main pattern found in that individual.
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A previous study has shown reduced ASM activity in non-lesional
and lesional AD epidermis compared to controls, while proposing re-
duced sphingomyelin levels were not caused by the downregulated
ASM levels [26]. In addition normal GBA activity in AD SC has been
reported [25]. The present study is the first to study in which both,
active GBA and ASM were localized throughout the whole epidermis
and related to changes observed in SC ceramide subclass profile in AD.
More specifically, we demonstrate that the location of active enzyme
rather than the location of expressed enzyme correlates with AD disease
manifestation. This elucidates why previously no correlations between
enzymes and SC lipids were observed [28], as detailed localization of
active GBA and ASM has never been described in AD. Due to the recent
development of visualization techniques by ABP-labeling and in-situ
zymography for GBA and ASM [44,52], their localization can now be
studied in detail. Besides to the aforementioned changes in localization
of active GBA and ASM in AD, we also observed, on a micro-level scale,
a high variation in location of active GBA and ASM. Lipid content over
depth has previously been shown to be homogeneous [53]. However,
because local changes are observed for the (active) enzymes GBA and
ASM, local differences in lipid composition cannot be excluded. No
techniques with sufficient resolution are available yet to measure these
changes in lipid compositions locally. The underlying reason for high
variation in the location of active enzyme is unknown, but literature
mentions changes in the micro-environment as one of the most plau-
sible reasons [29]. Changes in micro-environment may affect the local
distribution of microflora (which relates to our local changes in anti-
microbial peptide HBD-3 expression), and also the local acidic en-
vironment (so-called skin-pH). Literature reports slightly elevated levels
in skin-pH in AD [46], even in non-lesional skin [54]. This change in
skin-pH could affect the activity of GBA and ASM in vivo, as the optimal
pH value for GBA and ASM are respectively 4.5 and 5.6 [55]. In ad-
dition, we analyzed the skin-pH, but did not observe substantial dif-
ferences between healthy subjects and AD-patients. However, if these
environmental changes in acidity vary to a high extent on a micro-scale,
this would align with the micro-scale localization differences in active
GBA and ASM. Another important factor for optimal enzyme activity is
the presence of cofactors. Saposin C is necessary for proper GBA ac-
tivity, and dysfunction in this cofactor could lead to insufficient cer-
amide conversion, as is the case in specific Gaucher cohorts [56]. The
role of saposin C in relation to AD is unknown, but it has been reported
that protein amount of precursor prosaposin is decreased in AD [57]
which could hamper proper functioning of GBA.
GBA converts glucosylceramides into the final SC barrier ceramides.
Previously no difference in GBA activity between lesional and control
skin was found [25]. However, we observed that active GBA is less
localized around the SG/SC-interface and lower SC layers in lesional AD
skin compared to control. This is in line with previous observations by
Holleran et al., who demonstrated changes in localization of GBA ac-
tivity (relative increase in upper parts of the epidermis) in mice with a
skin barrier disruption [58]. In our study, the altered location of active
GBA correlates with a decreased amount of overall SC ceramide levels,
particularly the subclasses that cannot be synthesized by ASM. This
corresponds with the localization of active ASM being present in ad-
ditional (more outer) SC layers besides being mainly localized at the
SG/SC-interface, as observed in the control group. The increase of
ceramides [AS] and [NS] correlated to clinically relevant parameters
for skin barrier function (TEWL) and disease severity (SCORAD). Other
reported studies in different cohorts and skin diseases that found
comparable changes in ceramides [AS] and [NS] (reviewed by [19]),
implies that the by ASM derived [AS] and [NS] ceramides are involved
in circumstances relate to stressed/diseased skin. This could indicate
ASM has a different function than GBA in the skin, as they also have
different roles in other organs and tissues: GBA is a key lysosomal en-
zyme, responsible for main physiological functions of almost every cell,
and a key enzyme in glucosylceramide metabolism under healthy/
physiological conditions and is considered a housekeeping enzyme
[59]. On the contrary, ASM is usually referred as a mediator in pa-
thological processes like cell stress and apoptosis [60]. A switch from
physiological conditions towards pathophysiological conditions, like
observed here between healthy and AD, may imply that these enzymes
have comparable (patho)physiological roles in the skin as they have
elsewhere in the human body. Besides, the localization of expressed
TARC, a chemokine triggered in inflammatory diseases like AD, is also
changed in AD subjects and could be observed throughout the SC rather
than only in the viable epidermis or at the SG/SC-interface [61,62].
Note that these AD subjects did also demonstrate active ASM
throughout the SC.
Literature reports TARC as one of the most significant biomarkers to
date for diagnosing AD [63]. We did not observe a correlation between
the localization of TARC in the skin and systemic TARC analyzed from
plasma. However, visualizing this expressed biomarker in the epidermis
does already demonstrate local changes, that might not be visible sys-
temic yet. This all indicates that for interpreting local changes in AD
severity, visualization of the local epidermal environment may facil-
itate in elucidating differences between clinical appearances of AD
patients.
The reduction we found in [NP] ceramides (and increase in [AS]
and [NS]), can also – at least partially – be explained by changes in
dihydroceramide desaturase enzymes (DEGS1 and DEGS2), involved in
the conversion of [dS]-ceramides into respectively [S]-ceramides and
[P]-ceramides. An increase in expression/activity of DEGS1 relative to
DEGS2 would increase the amount of [S] ceramides at the expense of
[P] ceramides. The analysis of DEGS-enzymes is beyond the scope of
this manuscript, and currently no methods are available for visualizing
in-situ DEGS activity.
We have shown the importance of correct localization of SC en-
zymes and how this correlates with previously published characteristics
of AD, as well as SC lipid composition. We demonstrated changes in SC
lipid composition directly affect the skin barrier function (and in-
directly disease severity). As these changes originate (at least partially)
from changes in the activity of the enzymes, a possible new target for
therapy would be to restore the activity of GBA and ASM in AD skin to
that of control skin, thereby aiming for repairing the ceramide com-
position in AD.
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